<DOC>
	<DOC>NCT01720030</DOC>
	<brief_summary>We hypothesise that levosimendan will have a positive influence on renal function during acute kidney injury in adult intensive care patients.</brief_summary>
	<brief_title>Levosimendan in Acute Kidney Injury Study</brief_title>
	<detailed_description>The purpose of this trial is to evaluate whether the use of levosimendan is able to improve renal function.</detailed_description>
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Clinically diagnosed adult patients with AKI Failure to obtain written consent to participate from patient or legal representative (by deferred consent) Patients entering the ICU for postoperative observation with an estimated length of stay less than 24 hrs. Moribund patients Patients under the age of 18 Pregnancy Patients suffering from preexisting renal failure (elevated NGAL values without apparent rise in creatinine values) Renal replacement therapy initiated before admission due to Chronic Kidney Disease Hypersensitivity to levosimendan experienced by previous treatments Severe hypotension and tachycardia Significant mechanical obstruction affecting ventricular filling or outflow or both. Severe hepatic impairment (ALAT/ASAT&gt;400U/L) Patients will be excluded if the treating physician judges that study participation is undesirable for medical, medicalethical or other reasons Known history of Torsades de Pointes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Renal</keyword>
	<keyword>Acute Kidney Injury</keyword>
	<keyword>AKI</keyword>
	<keyword>Levosimendan</keyword>
	<keyword>Simdax</keyword>
	<keyword>Renal perfusion</keyword>
	<keyword>Mortality</keyword>
	<keyword>Renal flow</keyword>
</DOC>